Provided by Tiger Trade Technology Pte. Ltd.

Corcept Therapeutics

122.25
+1.200.99%
Post-market: 122.250.00000.00%19:58 EDT
Volume:656.44K
Turnover:80.15M
Market Cap:13.22B
PE:269.48
High:123.44
Open:121.48
Low:120.56
Close:121.05
52wk High:123.44
52wk Low:28.66
Shares:108.10M
Float Shares:96.44M
Volume Ratio:0.88
T/O Rate:0.68%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.4537
EPS(LYR):0.8200
ROE:8.23%
ROA:0.47%
PB:18.72
PE(LYR):149.09

Loading ...

BRIEF-Corcept To Resubmit NDA For Relacorilant As Treatment For Cushing's Syndrome Patients

Reuters
·
May 27

Corcept plans to resubmit FDA NDA for relacorilant in Cushing’s syndrome after CRL

Reuters
·
May 27

Corcept Therapeutics Inc - FDA Expects Pdufa Date Six Months After Nda Resubmission for Relacorilant

THOMSON REUTERS
·
May 27

Corcept to Resubmit Its New Drug Application for Relacorilant as a Treatment for Patients With Cushing’s Syndrome

THOMSON REUTERS
·
May 27

Does Corcept Therapeutics' (CORT) UBS Upgrade and Insider Gifting Reframe Its Oncology Ambitions?

Simply Wall St.
·
May 18

Corcept Therapeutics Shares Rise After UBS Upgrade

MT Newswires Live
·
May 14

Corcept Therapeutics Inc : UBS Raises to Buy From Neutral

THOMSON REUTERS
·
May 13

Corcept Therapeutics upgraded to Buy from Neutral at UBS

TIPRANKS
·
May 13

Corcept Therapeutics Raised to Buy From Neutral by UBS

Dow Jones
·
May 13

UBS Upgrades Corcept Therapeutics to Buy From Neutral, Adjusts Price Target to $72 From $44

MT Newswires Live
·
May 13

Corcept CEO Joseph Belanoff disposes 40,000 shares worth $2 million

Reuters
·
May 06

Corcept Therapeutics Signals Big Growth After Key Wins

TIPRANKS
·
May 05

Canaccord Genuity Remains a Buy on Corcept Therapeutics (CORT)

TIPRANKS
·
May 04

Corcept Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
May 04

Corcept Therapeutics price target raised to $75 from $60 at H.C. Wainwright

TIPRANKS
·
May 04

Corcept Therapeutics Inc. : H.c. Wainwright Raises Target Price to $75 From $60

THOMSON REUTERS
·
May 04

Is Corcept Therapeutics (CORT) Pricing Make Sense After Recent Volatility In The Share Price

Simply Wall St.
·
May 02

Corcept Therapeutics Is Maintained at Overweight by Piper Sandler

Dow Jones
·
May 02

Stock Track | Corcept Therapeutics Soars 5.33% Intraday After Piper Sandler Raises Price Target to $88

Stock Track
·
May 01

Corcept Therapeutics price target raised to $88 from $73 at Piper Sandler

TIPRANKS
·
May 01